drug launch

New Era; New Launch Excellence Blueprint for 2021-2022

Life Sciences’ Transformative Journey to Consolidation in 2021 and What to Expect in 2022

New Era; New Launch Excellence Blueprint for 2021-2022

John Constantine, Senior VP at Orchestrall, Inc: How to Accelerate Drug and Device Launch in the Post-COVID World

Episode 2: How to Accelerate Drug and Device Launch in the Post-COVID World

New Era; New Launch Excellence Blueprint for 2021-2022

The Ultimate Guide to Omnichannel Education

How Life Sciences Companies Can Level Up Healthcare Education in Post-COVID Era

Four Fundamentals for Telling Your Clinical Evidence Story

ACTO Named One of the 2019 PM360 ELITE 100

Channel Partners: Gaining Visibility and Creating Accountability

CEO Parth Khanna’s Interview with Dr. Bertalan Mesko from The Medical Futurist, on Life Sciences Education

ACTO Kicks Off 2021 with Chart-Topping Growth

ACTO Closes $11.5M Series A Round to Accelerate Virtual Transformation for Life Sciences Companies

What Does ACTO’s Acquisition of CoHealth Mean for Patient Education?

ACTO Acquires Scrimmage

Omnichannel Education For The Life Sciences

Exclusive ACTO Omnichannel Platform Mini Demo

ACTO Emerges as a Leader in Life Sciences Commercialization; Closes Strong Calendar Year 2018 with 184% Revenue Growth and Doubled Customer Base

Critical Insights from Industry Leaders for Successful Implementation of Commercial Digital Transformation

ACTO Acquires Scrimmage, Disrupting Life Sciences Learning and Engagement Market

ACTO Achieves 158% Year to Date Revenue Growth in 2019 and Has Digitally Transformed Over 50 Life Sciences Companies

Channel Partners: Accessibility is the Magic Word

When the Rubber Meets the Road, Don’t Slip
Selling on Clinical Value – Action Plan


Episode 3: The New Model for Crisis Leadership in Life Sciences

The Triple A Initiative: ACTO, Axiom, and AstraZeneca
